PT  - JOURNAL ARTICLE
AU  - Clapham, Hannah E
AU  - Chia, Wanni
AU  - Zhang, Jinyan
AU  - Wang, Lin-Fa
AU  - Tam, Clarence C
TI  - SARS-CoV-2 neutralising antibody activity in a highly vaccinated population: Longitudinal serology studies in Singapore
AID  - 10.1101/2022.05.29.22275748
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.05.29.22275748
4099  - http://medrxiv.org/content/early/2022/05/30/2022.05.29.22275748.short
4100  - http://medrxiv.org/content/early/2022/05/30/2022.05.29.22275748.full
AB  - Background There is continuing uncertainty regarding the longevity of immunological responses to both SARS-CoV-2 natural infection and COVID-19 vaccines.Methods We analysed data from two serological cohorts in Singapore among residents of a COVID-19 affected migrant worker dormitory between May-July 2020, and among mRNA COVID-19 vaccine recipients between May 2021 and January 2022. We compared SARS-CoV-2 neutralising antibody levels by age group, sex, presence of pre-existing medical conditions, type of mRNA vaccine received and number of doses received. We investigated the effect of time since infection or vaccination on antibody levels in naturally infected individuals and two- and three-dose vaccinees.Results After two vaccine doses, neutralising antibody responses were higher in Spikevax (Moderna) recipients, females, younger individuals and those with no underlying medical conditions. However, antibody levels waned to similar levels in all groups over time. A third dose boosted these to similarly high levels in all groups. Waning was apparent among two-dose but not three-dose recipients over a period of six months. Both two and three-dose vaccine recipients showed consistently higher neutralising antibody levels compared with naturally infected individuals over the 12-week period following infection or vaccination.Conclusions Our findings support the broad use of booster doses to improve population protection from COVID-19. However, recent increases in transmission of new SARS-CoV-2 variants, even in the presence of high levels of neutralising antibody in a highly vaccinated population, point to vaccine breakthrough as an important mechanism for maintaining SARS-CoV-2 circulation and indicate the need for variant-specific or universal COVID-19 vaccines.Summary Younger individuals, females and those with no pre-existing conditions have higher neutralising antibody levels after two doses of COVID-19 mRNA vaccine. Subsequently these wane to levels seen in other groups. A booster dose promotes similarly high levels in all groups.Competing Interest StatementL-FW and WNC are co-inventors of a patent application for the cPass test kit. The remaining authors declare no competing interests in relation to this work.Funding StatementThe community cohort study is supported by a Wellcome Trust grant (grant number: 221013/Z/20/Z). The serological test development at Duke-NUS was supported by grants from the Singapore National Medical Research Council (STPRG-FY19-001 and COVID19RF-003)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:National University of Singapore Institutional Review BoardI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors